B-PRECISE-01 Study: A phase lb trial of MEN1611, a PI3K Inhibitor, combined with trastuzumab +/- fulvestrant for the treatment of HER2-positive advanced or metastatic breast cancer.

Affiliation auteurs!!!! Error affiliation !!!!
TitreB-PRECISE-01 Study: A phase lb trial of MEN1611, a PI3K Inhibitor, combined with trastuzumab +/- fulvestrant for the treatment of HER2-positive advanced or metastatic breast cancer.
Type de publicationJournal Article
Year of Publication2019
AuteursPiccart-Gebhart MJ, Aftimos PGeorges, Duhoux FP, Wildiers H, Isambert N, Campone M, Tosi D, Varga AI, Boni V, Doger B, Corbacho JGarcia, Jimenez-Rodriguez B, Borrego MRuiz, Saura C, Arkenau H-T, Wardley AM, Troconiz IF, Binaschi M, Simonelli C, Pellacani AUgo
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume37
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2019.37.15_suppl.TPS1101